Sarcopenia With Limited Mobility: An International Consensus
By J. Morley, A. Abbatecola, J. Argilés, Vickie E. Baracos, J. Bauer, S. Bhasin, T. Cederholm, Andrew J. Stewart Coats, Steve Cummings, W. Evans and 21 more. Journal of the American Medical Directors Association, 2011
1,013 citations recorded by the source corpus.
A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that “Sarcopenia, ie, reduced muscle mass, with limited mobility” should be considered an important clinical entity and that most older persons should be screened for this condition. “Sarcopenia with limited mobility” is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s. “A word is not a crystal, transparent and unchanged; it is the skin of a living thought and may vary greatly in color and content according to the circumstances and the time when it is used.”—Oliver Wendell Holmes
Subfields: Geriatrics and Gerontology, Nutrition and Dietetics, Physiology
View Paper: https://www.semanticscholar.org/paper/2dffe2f9597e732f5c5e41bc3cbb55aaa81dccb0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nutrition and Dietetics
In Physiology
Citations in the corpus
- Sarcopenia: revised European consensus on definition and diagnosis (2018, background): “In terms of human health, sarcopenia increases risk of falls and fractures [10, 11]; impairs ability to perform activities of daily living [12]; is associated with cardiac disease [13], respiratory disease [14] and cognitive impairment [15]; leads to mobility disorders [2]; and contributes to lowere”
- Inflammation and sarcopenia: A systematic review and meta-analysis. (2017, neutral): “According to the recent definitions of several working groups, sarcopenia is described as a syndrome characterized by a loss of muscle mass and strength with functional impairment and adverse outcomes [2], [3].”
- Frailty Consensus: A Call to Action (2013, neutral): “27 e 31 3.”
- Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta‐analysis (2019, result): “This highlights the importance of muscle strength or physical performance in the sarcopenia definition, in line with current definitions.(58,59,61,62,68,93) However, literatures also showed the value of including muscle mass in sarcopenia definitions.”